![Barbara Coles Bsc (Hons), MPhil](https://profiles-cardiff.imgix.net/attachments/4140?w=200&h=200&auto=format&crop=faces&fit=crop&q=90")
Mrs Barbara Coles
Bsc (Hons), MPhil
Clinical Innovation Hub Manager, ACCELERATE Project Manager, Innovation and Business Lead – Pentre Awel
Overview
I am a reliable and proactive individual with a broad research background and comprehensive experience in project management, operational delivery, team management and innovation through co-development and engagement. I bring forward established working collaborations and networks across industry, public and third sector.
I programme managed the Clinical Innovation Accelerator for Cardiff, an ERDF Accelerate programme (2018-2023). I also support project management activities, strategic development, and implementation for CIH, providing the main link between Cardiff University and partners. Barbara actively supports initiatives in the Clinical Innovation Partnership between Cardiff University and Cardiff and Vale University Health Board, this a crucial pipeline for clinical innovation activities and projects. Barbara is lead for innovation and business at Pentre Awel – a Health and Wellness initiative in Llanelli.
Publication
2014
- Fielding, C. A. et al. 2014. Interleukin-6 signaling drives fibrosis in unresolved inflammation. Immunity 40(1), pp. 40-50. (10.1016/j.immuni.2013.10.022)
2013
- Raby, A. et al. 2013. Targeting the TLR co-receptor CD14 with TLR2-derived peptides modulates immune responses to pathogens. Science Translational Medicine 5(185), article number: 185ra64. (10.1126/scitranslmed.3005544)
2011
- Clark, S. R. et al. 2011. Esterified eicosanoids are acutely generated by 5-lipoxygenase in primary human neutrophils and in human and murine infection. Blood 117(6), pp. 2033-2043. (10.1182/blood-2010-04-278887)
- Raby, A. et al. 2011. TLR activation enhances C5a-induced pro-inflammatory responses by negatively modulating the second C5a receptor, C5L2. European Journal of Immunology 41(9), pp. 2741-2752. (10.1002/eji.201041350)
2010
- Coles, B., Colmont, C. S., Fielding, C. A., Kift-Morgan, A., Hams, E., Topley, N. and Jones, S. A. 2010. Local manipulation of IL-6 trans-signaling therapeutically enhances anti-microbial host defense [Abstract]. Cytokine 52(1-2), pp. 80-81. (10.1016/j.cyto.2010.07.335)
2009
- Raby, A. et al. 2009. Soluble TLR2 reduces inflammation without compromising bacterial clearance by disrupting TLR2 triggering. The Journal of Immunology 183(1), pp. 506-517. (10.4049/jimmunol.0802909)
- Maskrey, B. H. et al. 2009. Activated platelets and monocytes generate four hydroxyphosphatidylethanolamines via lipoxygenase [Addition]. Journal of Biological Chemistry 284(37), pp. 25460. (10.1074/jbc.A611776200)
- Morgan, A. H. et al. 2009. Phosphatidylethanolamine-esterified eicosanoids in the mouse: tissue localization and inflammation-dependent formation in Th-2 disease. Journal of Biological Chemistry 284(32), pp. 21185-21191. (10.1074/jbc.M109.021634)
2008
- Morton, J. et al. 2008. Circulating neutrophils maintain physiological blood pressure by suppressing bacteria and IFN -dependent iNOS expression in the vasculature of healthy mice. Blood 111(10), pp. 5187-5194. (10.1182/blood-2007-10-117283)
- Coles, B., Wilton, L. A. K., Good, M. A., Chapman, P. F. and Wann, K. T. 2008. Potassium channels in hippocampal neurones are absent in a transgenic but not in a chemical model of Alzheimer's disease. Brain Research 1190, pp. 1-14. (10.1016/j.brainres.2007.10.071)
2007
- Coles, B., Fielding, C. A., Rose-John, S., Scheller, J., Jones, S. A. and O'Donnell, V. B. 2007. Classic interleukin-6 receptor signaling and interleukin-6 trans-signaling differentially control angiotensin II-dependent hypertension, cardiac signal transducer and activator of transcription-3 activation, and vascular hypertrophy in vivo. American Journal of Pathology 171(1), pp. 315-325. (10.2353/ajpath.2007.061078)
2006
- Anning, P. B. et al. 2006. Nitric Oxide deficiency promotes vascular side effects of cyclooxygenase inhibitors. Blood 108(13), pp. 4059-4062. (10.1182/blood-2006-02-005330)
2005
- Williams, P. C. et al. 2005. In vivo aspirin supplementation inhibits nitric oxide consumption by human platelets. Blood 106(8), pp. 2737-2743. (10.1182/blood-2005-02-0664)
2004
- Coffey, M. J., Coles, B., Locke, M., Bermudez-Fajardo, A., Williams, P. C., Jarvis, G. E. and O'Donnell, V. B. 2004. Interactions of 12-lipoxygenase with phospholipase A2 isoforms following platelet activation through the glycoprotein VI collagen receptor. FEBS Letters 576(1-2), pp. 165-168. (10.1016/j.febslet.2004.09.007)
- Coffey, M. J., Jarvis, G. E., Gibbins, J. M., Coles, B., Barrett, N. E., Wylie, O. R. and O'Donnell, V. B. 2004. Platelet 12-lipoxygenase activation via glycoprotein VI: involvement of multiple signaling pathways in agonist control of H(P)ETE synthesis. Circulation Research 94(12), pp. 1598-1605. (10.1161/01.RES.0000132281.78948.65)
2002
- Coles, B., Bloodsworth, A., Clark, S. R., Lewis, M. J., Cross, A. R., Freeman, B. A. and O'Donnell, V. B. 2002. Nitrolinoleate inhibits superoxide generation, degranulation, and integrin expression by human neutrophils: novel antiinflammatory properties of nitric oxide-derived reactive species in vascular cells. Circulation Research 91(5), pp. 375-381. (10.1161/01.RES.0000032114.68919.EF)
2001
- Coffey, M. J. et al. 2001. Catalytic consumption of nitric oxide by 12/15- lipoxygenase: inhibition of monocyte soluble guanylate cyclase activation. Proceedings of the National Academy of Sciences of the United States of America (PNAS) ISSN 1091-6490 98(14), pp. 8006-8011. (10.1073/pnas.141136098)
Erthyglau
- Fielding, C. A. et al. 2014. Interleukin-6 signaling drives fibrosis in unresolved inflammation. Immunity 40(1), pp. 40-50. (10.1016/j.immuni.2013.10.022)
- Raby, A. et al. 2013. Targeting the TLR co-receptor CD14 with TLR2-derived peptides modulates immune responses to pathogens. Science Translational Medicine 5(185), article number: 185ra64. (10.1126/scitranslmed.3005544)
- Clark, S. R. et al. 2011. Esterified eicosanoids are acutely generated by 5-lipoxygenase in primary human neutrophils and in human and murine infection. Blood 117(6), pp. 2033-2043. (10.1182/blood-2010-04-278887)
- Raby, A. et al. 2011. TLR activation enhances C5a-induced pro-inflammatory responses by negatively modulating the second C5a receptor, C5L2. European Journal of Immunology 41(9), pp. 2741-2752. (10.1002/eji.201041350)
- Coles, B., Colmont, C. S., Fielding, C. A., Kift-Morgan, A., Hams, E., Topley, N. and Jones, S. A. 2010. Local manipulation of IL-6 trans-signaling therapeutically enhances anti-microbial host defense [Abstract]. Cytokine 52(1-2), pp. 80-81. (10.1016/j.cyto.2010.07.335)
- Raby, A. et al. 2009. Soluble TLR2 reduces inflammation without compromising bacterial clearance by disrupting TLR2 triggering. The Journal of Immunology 183(1), pp. 506-517. (10.4049/jimmunol.0802909)
- Maskrey, B. H. et al. 2009. Activated platelets and monocytes generate four hydroxyphosphatidylethanolamines via lipoxygenase [Addition]. Journal of Biological Chemistry 284(37), pp. 25460. (10.1074/jbc.A611776200)
- Morgan, A. H. et al. 2009. Phosphatidylethanolamine-esterified eicosanoids in the mouse: tissue localization and inflammation-dependent formation in Th-2 disease. Journal of Biological Chemistry 284(32), pp. 21185-21191. (10.1074/jbc.M109.021634)
- Morton, J. et al. 2008. Circulating neutrophils maintain physiological blood pressure by suppressing bacteria and IFN -dependent iNOS expression in the vasculature of healthy mice. Blood 111(10), pp. 5187-5194. (10.1182/blood-2007-10-117283)
- Coles, B., Wilton, L. A. K., Good, M. A., Chapman, P. F. and Wann, K. T. 2008. Potassium channels in hippocampal neurones are absent in a transgenic but not in a chemical model of Alzheimer's disease. Brain Research 1190, pp. 1-14. (10.1016/j.brainres.2007.10.071)
- Coles, B., Fielding, C. A., Rose-John, S., Scheller, J., Jones, S. A. and O'Donnell, V. B. 2007. Classic interleukin-6 receptor signaling and interleukin-6 trans-signaling differentially control angiotensin II-dependent hypertension, cardiac signal transducer and activator of transcription-3 activation, and vascular hypertrophy in vivo. American Journal of Pathology 171(1), pp. 315-325. (10.2353/ajpath.2007.061078)
- Anning, P. B. et al. 2006. Nitric Oxide deficiency promotes vascular side effects of cyclooxygenase inhibitors. Blood 108(13), pp. 4059-4062. (10.1182/blood-2006-02-005330)
- Williams, P. C. et al. 2005. In vivo aspirin supplementation inhibits nitric oxide consumption by human platelets. Blood 106(8), pp. 2737-2743. (10.1182/blood-2005-02-0664)
- Coffey, M. J., Coles, B., Locke, M., Bermudez-Fajardo, A., Williams, P. C., Jarvis, G. E. and O'Donnell, V. B. 2004. Interactions of 12-lipoxygenase with phospholipase A2 isoforms following platelet activation through the glycoprotein VI collagen receptor. FEBS Letters 576(1-2), pp. 165-168. (10.1016/j.febslet.2004.09.007)
- Coffey, M. J., Jarvis, G. E., Gibbins, J. M., Coles, B., Barrett, N. E., Wylie, O. R. and O'Donnell, V. B. 2004. Platelet 12-lipoxygenase activation via glycoprotein VI: involvement of multiple signaling pathways in agonist control of H(P)ETE synthesis. Circulation Research 94(12), pp. 1598-1605. (10.1161/01.RES.0000132281.78948.65)
- Coles, B., Bloodsworth, A., Clark, S. R., Lewis, M. J., Cross, A. R., Freeman, B. A. and O'Donnell, V. B. 2002. Nitrolinoleate inhibits superoxide generation, degranulation, and integrin expression by human neutrophils: novel antiinflammatory properties of nitric oxide-derived reactive species in vascular cells. Circulation Research 91(5), pp. 375-381. (10.1161/01.RES.0000032114.68919.EF)
- Coffey, M. J. et al. 2001. Catalytic consumption of nitric oxide by 12/15- lipoxygenase: inhibition of monocyte soluble guanylate cyclase activation. Proceedings of the National Academy of Sciences of the United States of America (PNAS) ISSN 1091-6490 98(14), pp. 8006-8011. (10.1073/pnas.141136098)
Biography
Barbara is the Clinical Innovation Hub (CIH) Manager in the School of Medicine, Cardiff University. She supports overall project management activities, strategic development and implementation for CIH, providing the main link between Cardiff University and the Accelerate partners. Barbara actively supports initiatives in the Clinical Innovation Partnership between Cardiff University and Cardiff and Vale University Health Board, this a crucial pipeline for clinical innovation activities and projects. Barbara completed her MPhil at Cardiff University with a research career spanning the electrophysiology of potassium channels in Alzheimer’s, nitric oxide in vasodilation and coagulation and inflammation (peritoneal and sepsis). As a PRINCE 2 practitioner, project management has included UTA Wellcome awards and as the Outputs Administrator for Research Excellence Framework (REF 2014), School of Medicine.
Barbara is the project manager for the Clinical Innovation Accelerator (CIA) within the School of Medicine, Cardiff University. Supported by a dedicated team of 17, CIA specialises in the adoption of clinical or patient focused innovative projects by providing support through NHS, academic and enterprise expertise, collaboration and engagement. The team’s wide-ranging scientific knowledge combined with clinical, health, business, legal, industrial and academic expertise enables extensive scoping, exploration with maximisation of project potential and development to transform health and patient care whilst supporting Welsh economic growth.
Honours and awards
My track record is evidenced by the successful delivery of Accelerate for Cardiff and attaining an Outstanding Contribution Award for the outcomes delivered - 2022
